Recurrent respiratory papillomatosis: role of bevacizumab and HPV vaccination. A literature review with case presentations

Sporeni, Silvio; Rifaldi, Francesca; Lanzetta, Irene; Imarisio, Ilaria; Montagna, Benedetta; Serra, Francesco; Agustoni, Francesco; Pedrazzoli, Paolo; Benazzo, Marco; Bertino, Giulia

doi:10.2478/raon-2025-0010

References

Andrei EC, Baniţă IM, Munteanu MC, Busuioc CJ, Mateescu GO, Mălin RD, et al. Oral papillomatosis: its relation with human papilloma virus infection and local immunity - an update. Medicina (Kaunas) 2022; 58: 1103. doi: 10.3390/medicina58081103
Open DOI Search in Google Scholar Back to article
Betz SJ. HPV-related papillary lesions of the oral mucosa: a review. Head Neck Pathol 2019; 13: 80-90. doi: 10.1007/s12105-019-01003-7
Open DOI Search in Google Scholar Back to article
Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-54. doi: 10.1016/j.vaccine.2012.05.070
Open DOI Search in Google Scholar Back to article
Syrjänen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003; 192: 123-8. doi: 10.1007/s00430-002-0173-7
Open DOI Search in Google Scholar Back to article
Welschmeyer A, Berke G S. An updated review of the epidemiological factors associated with recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 2021; 6: 226-33. doi: 10.1002/lio2.521
Open DOI Search in Google Scholar Back to article
Wang HFan, Wang SS, Tang YJ, Chen Y, Zheng M, Tang YL, et al. The double-edged sword-how human papillomaviruses interact with immu-nity in head and neck cancer. Front Immunol 2019; 10: 653. doi: 10.3389/fimmu.2019.00653
Open DOI Search in Google Scholar Back to article
Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017; 9: 229. doi: 10.3390/v9080229
Open DOI Search in Google Scholar Back to article
Langer C, Wittekindt C, Wolf G. [Recurrent respiratory papillomatosis: current information on diagnosis and therapy]. [German]. Onkol up2date 2020; 2: 107-18. doi: 10.1055/a-1132-0051
Open DOI Search in Google Scholar Back to article
San Giorgi MRM, van den Heuvel ER, Tjon Pian Gi REA, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol 2016; 41: 448-53. doi: 10.1111/coa.12565
Open DOI Search in Google Scholar Back to article
Evers G, Schliemann C, Beule A, Schmidt LH, Schulze AB, Kessler C, et al. Long-term follow-up on systemic bevacizumab treatment in recurrent res-piratory papillomatosis. Laryngoscope 2021; 131: E1926-E33. doi: 10.1002/lary.29351
Open DOI Search in Google Scholar Back to article
Seedat RY. Juvenile-onset recurrent respiratory papillomatosis diagnosis and management – a developing country review. Pediatr Heal Med Ther 2020; 11: 39-46. doi: 10.2147/PHMT.S200186
Open DOI Search in Google Scholar Back to article
Ouda AM, Elsabagh AA, Elmakaty IM, Gupta I, Vranic S, Hamda Al-Thawadi H, et al. HPV and recurrent respiratory papillomatosis: a brief review. Life 2021; 11: 1-17. doi: 10.3390/life11111279
Open DOI Search in Google Scholar Back to article
Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med 2017; 126: 116.21. doi: 10.1016/j.rmed.2017.03.030
Open DOI Search in Google Scholar Back to article
Mauz P S, Zago M, Kurth R, Pawlita M, Holderried M, Thiericke J, et al. A case of recurrent respiratory papillomatosis with malignant transformation, HPV11 DNAemia, high L1 antibody titre and a fatal papillary endocardial lesion. Virol J 2014; 11: 1-6. doi: 10.1186/1743-422X-11-114
Open DOI Search in Google Scholar Back to article
Bertino G, Pedretti F, Mauramati S, Filauro M, Vallin A, Mora F, et al. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study. Acta Otorhinolaryngol Ital 2023; 43: S111-S122. doi: 10.14639/0392-100X-suppl.1-43-2023-14
Open DOI Search in Google Scholar Back to article
Torres-Canchala L, Cleves-Luna D, Arias-Valderrama O, Candelo E, Guerra MA, Pachajoa H, et al. Systemic bevacizumab for recurrent respiratory papillomatosis: a scoping review from 2009 to 2022. Child 2022; 10: 54. doi: 10.3390/children10010054
Open DOI Search in Google Scholar Back to article
Derkay CS, Wikner EE, Pransky S, Best SR, Zur K, Sidell DR, et al. Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope 2023; 133: 2-3. doi: 10.1002/lary.30180
Open DOI Search in Google Scholar Back to article
Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel RNPM. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol 2022; 279: 4229-40. doi: 10.1007/s00405-022-07388-6
Open DOI Search in Google Scholar Back to article
Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005; 114: 463-71. doi: 10.1177/000348940511400608
Open DOI Search in Google Scholar Back to article
Bergler WF, Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2000; 257: 263-9. doi: 10.1007/s004050050236
Open DOI Search in Google Scholar Back to article
Patel A, Orban N. Infantile recurrent respiratory papillomatosis: review of adjuvant therapies. J Laryngol Otol 2021; 135: 958-63. doi: 10.1017/S0022215121002322
Open DOI Search in Google Scholar Back to article
Tjon Pian GiREA, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®). Eur Arch Otorhinolaryngol 2012; 269: 361-2. doi: 10.1007/s00405-011-1804-7
Open DOI Search in Google Scholar Back to article
Rahbar R, Vargas SO, Folkman J, McGill TJ, Healy GB, Tan X, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2005; 114: 289-95. doi: 10.1177/000348940511400407
Open DOI Search in Google Scholar Back to article
Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett 2014; 8: 1912-8 doi: 10.3892/ol.2014.2486
Search in Google Scholar Back to article
Ryan MA, Leu GR, Upchurch PA, Tunkel DE, Walsh JM, Boss EF, et al. Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope 2021; 131: 1138-46. doi: 10.1002/lary.29084
Open DOI Search in Google Scholar Back to article
Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 2011; 120: 627-34. doi: 10.1177/000348941112001001.
Open DOI Search in Google Scholar Back to article
Zagzoog FH, Mogharbel AM, Alqutub A, Bukhari M, Almohizea MI. Intralesional cidofovir vs. bevacizumab for recurrent respiratory pap-illomatosis: a systematic review and indirect meta-analysis. Eur Arch Otorhinolaryngol 2024; 281: 601-27. doi: 10.1007/s00405-023-08279-0
Open DOI Search in Google Scholar Back to article
Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J. Voice 2015; 29: 223-9. doi: 10.1016/j. jvoice.2014.08.003
Open DOI Search in Google Scholar Back to article
Mau T, Amin MR, Belafsky PC, Best SR, Friedman AD, Klein AM, et al. Interim results of a phase 1/2 open-label study of INO-3107 for HPV-6 and/or HPV-11-associated recurrent respiratory papillomatosis. Laryngoscope 2023; 133: 3087-93. doi: 10.1002/lary.30749
Open DOI Search in Google Scholar Back to article
Nagel S, Busch C, Blankenburg T, Schütte W. [Treatment of respiratory papillomatosis − a case report on systemic treatment with bevacizumab]. [German]. Pneumologie 2009; 63: 387-9. doi: 10.1055/s-0029-1214714
Open DOI Search in Google Scholar Back to article
Best S R, Mohr M, Zur K. B. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope 2017; 127: 2225-9. doi: 10.1002/lary.26662
Open DOI Search in Google Scholar Back to article
Allen CT. Biologics for the treatment of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012; 54: 769-77. doi: 10.1016/j.otc.2021.05.002
Open DOI Search in Google Scholar Back to article
Yiu Y, Fayson S, Smith H, Matrka L. Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2019; 128: 309-15. doi: 10.1177/0003489418821695
Open DOI Search in Google Scholar Back to article
Chirilǎ M, Bolboacǎ SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2014; 271: 1135-42. doi: 10.1007/s00405-013-2755-y
Open DOI Search in Google Scholar Back to article

Recurrent respiratory papillomatosis: role of bevacizumab and HPV vaccination. A literature review with case presentations

References

Paradigm

My account